Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Multicenter, Randomized, Double-Blind, Active-Control Study to Evaluate the Efficacy and Safety of Nivolumab Administered in Combination With IPI-549 Compared to Nivolumab Monotherapy in the Treatment of Patients With Immune Therapy-Naive, Advanced Urothelial Carcinoma

Trial Profile

A Phase 2, Multicenter, Randomized, Double-Blind, Active-Control Study to Evaluate the Efficacy and Safety of Nivolumab Administered in Combination With IPI-549 Compared to Nivolumab Monotherapy in the Treatment of Patients With Immune Therapy-Naive, Advanced Urothelial Carcinoma

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 31 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IPI 549 (Primary) ; Nivolumab (Primary)
  • Indications Bladder cancer; Carcinoma; Urogenital cancer
  • Focus Therapeutic Use
  • Acronyms MARIO-275
  • Sponsors Infinity Pharmaceuticals
  • Most Recent Events

    • 30 Oct 2019 According to an Infinity Pharmaceuticals media release, the company plans on completing enrollment during 2020.
    • 26 Jul 2019 Status changed from not yet recruiting to recruiting.
    • 06 Jun 2019 Planned number of patients changed from 150 to 160.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top